All Episodes
Molecule to Market: Inside the outsourcing space — 284 episodes
What Pharma really needs From CDMOs today
The CSO Staying Ahead of the CDMO Curve
Leading a State Owned CDMO
CDMO Live Europe: When Outsourcing Goes Wrong 2026
From the Army Commander to the CDMO Corner Office
From Family Pharma to Global injectables CDMO
Meet the Supply Chain Wizard
Building a Canadian CDMO from grad school
From Big Pharma to Biotech CEO
From Lab to Boardroom at Sartorius
CDMO Live Europe: State of Contract Manufacturing 2026
Codexis at TIDES - Stereochemistry in RNA Manufacturing: Signal or Noise?
Navigating global supply chains at Big Pharma
Bora Live Panel - The Voice of the Customer
The Making of a CGT CDMO Builder
Inside the mind of the CMO outsourcer
The unconventional CEO
The Indiana boy driving CGT development
DCAT Live - Morgan Stanley CDMO CEO Dinner
DCAT Live Panel - Stick or Twist with Capacity in Times of Uncertainty
From consulting stay at home dad to global CRO CEO
From big pharma manufacturing lead to CDMO CEO
M2M Pulse: 7 Trends CDMO You Can’t Ignore
25+ years & 200+ deals - meet the prolific pharma dealmaker
The 30-year, overnight success
The CDMO CEO Operator Playbook for 2026
The AI CEO changing pharma from the inside
CDMO & C-suite headwinds for 2026
Insights from JPM
CDMO C-suite optimism pulse for 2026
The AI entrepreneur fighting against cancer
25+ years as pharma-focused PE fund
2025 Unwrapped: Top 5 Episodes
Doctor Entrepreneur who pulled off a $1.4b exit
M2M Monitor Special - 2026
The master building CEO leading Codis
From R&D to CRO CEO
M&A Roundtable Q4 2025 – Reflections and Predictions
From Pharma to CRO entrepreneur
The CEO leading Ensera's evolution
CPHI 2025 wrap-up
20 years of CPHI - Veterans Guide
Themes from PBOA Conference 2025
The understated CDMO CCO
The CEO driving change at Curia
The People-first CEO of FUJIFILM Biotechnologies
Driving growth and removing waste for big pharma
Riding the ups and downs of entrepreneurship
Unlocking CDMO growth via commercial excellence
Pharma services market sentiment at the midpoint of 25
Doc to CEO - 40 years of reinvention in biopharma
Meet the new boss of CPHI Europe
30 years on the rollercoaster of clinical trials
The rain-making, 2X exit founder
The Indian CEO driving change
40 years, 6 exits - a CEO addict
CDMO Live insights: Industry leaders on the future of pharma
The learning curve of a biotech founder/CSO
The cancer Doc, driven by impact
The GM focused on inhaled & nasal drugs
The impact of a CEO who loves to work
From brink of bankruptcy to boom
The CEO addicted to challenge
The COO leveraging the ‘power of we’
The pharma CEO focused on US commercial growth
The Spanish solid state specialist
The bullish CDMO CEO making bold moves
Geordie lad done good in pharma
The CEO driven by lentiviral vector success
The CRDMO CEO making his luck
The biotech CEO focused on curing paediatric deafness
Inside the mind of the CDMO customer
The master-builder now on a cell therapy crusade
From astrophysicist to biopharma industry leader
From Big Pharma to Snapdragon
The LATAM CRO Queen
The pulse of Big Pharma CEOs
How to plan for life sciences events in 2025
Biopharma Global Supply veteran
Meet the healthcare futurist
The dynamic duo driving global growth
Biopharma Insights: Live from J.P. Morgan
The CEO making a global impact
2024 reflections and 2025 outlook in pharma services
From questions to answers: Celebrating 200 episodes
Charles River's lifelong CDMO leader
The pharma ingredients disruptor
Baking success to IQVIA exit
The biotech-MedTech CEO tackling obesity
Delhi boy, done good
Meet the Top Gun CDMO Maverick
Tasty Topics: Navigating Novo Nordisk’s Acquisition of Catalent
Pfizer's retired manufacturing veteran
Reimagining drug development
A lifetime of drug hunting
The pink-haired CEO
The Harvard spin-out disrupting drug discovery
The rare disease champion
The VC Biotech investor
The diamond in the rough
One-hour special - The President of the PBOA
The puzzle-solving CEO
Summer sentiment: A life science industry check-in & where you'll find me
Pivoting to partnership success in clinical trial
A Sterling, CDMO leader
AI as a force for good in drug development
Harnessing tech to improve the economics of making medicine
Tasty Topics: Addressing the potential impact of the BIOSECURE Act
Becoming...a world class scientific leader
Mission-driven doctor, inventor & entrepreneur
The boomerang boy impacting gene therapies
Taking on the biologics CDMOs from down under
A true nerd of CGT
The virtual and decentralized clinical trials specialists
Jumping into CDMO after a lifetime as a sponsor
Zero to a billion... A CDMO original - part 2
Zero to a billion... A CDMO original - part 1
Dan’s the man...at Custom Biologics
Celebrating female talent in life sciences
The power of peptides
From Pfizer to CDMO carve-out
One-hour special: Meet the next big thing in obesity
M&A Roundtable and 2024 Predictions
Transforming a family pharma firm
From MassBio... to the world
From banking to biotech
Dealing with downturns... and the menopause.
The dealmaker now redefining commercialization
The biotech CDMO planning to impact the US
Molecule to Market: Our top trends 2023; part 2
Outsourcing in Ontario - on the cusp of greatness
Discover Diana of Dalriada
Molecule to Market: Our top trends 2023, part 1
Expert to Entrepreneur
The lab model of the future?
Look into 2024: Events Roundtable special
The problem-solving CMC consultant
Microsoft talks to Molecule to Market
Biopharma innovation in motion
Say hello to a “CTDMO”
The involuntary entrepreneur chemist
A passion for pharma packaging
M2M meets Moderna & CPHI Conversations
Launching a technology-forward CDMO
Designing facilities today for tomorrow’s medicines
The problem-solving biopharma veteran
The servant leader creating the next generation CDMO
From Powdersize to Microsize
The mission-driven biotech CEO
Foot on the pedal for Predictive Oncology
One-hour special: The biopharma outsourcer
From rural roots to global pharma leader
Igniting biotech innovation
From CDMO exit to CDMO+
From MBO to global, family-run CRO
Attracting and retaining the best talent; a roundtable special
Breathing life into high potential medicines
Molecule to Market is on the move...
Barbara’s journey into Biopharma
The CDMO CEO that doesn’t sugarcoat
Wheeler CDMO Avengers...assemble!
The future is bright, the future is CGT
The biopharma boss on a mission against mental health disorders
From semiconductors to life sciences
The CRO scientist turned entrepreneur
CDMO poacher turned biotech gamekeeper
Q123 M&A roundtable
Meet the future of bioreactors
Meet the lean, keen biotech
Why biotechs are feeling the bite
The Amalgamator of Biz and Bio
The 30-year biotech and CDMO entrepreneur
The ATMP and CDMO deal maker
From AZ to CRO Founder
The iterative nature of emerging therapeutics
Think Star Trek, Think Smart Labs
Founding and selling three bio CDMOs - Part 2
Founding and selling three bio CDMOs - Part 1
Network like a pro
Diversity in life sciences
The CDMO CEO on the frontline of a Covid mission
Industry insights you cannot afford to miss
The Puzzle-Solving Lifelong Science Geek
The CDMO with a capital D
100 episodes of Molecule to Market: looking back, lessons & laying the land for 101
Raman’s review of life science in 2022
A blast from the life science past
Tackling the 3 Big C’s: CDMO Career, Children & Cancer
Mystic Miller’s review of ’22 and predictions for ’23
Top 5 episodes of all time
CPHI 2022 - Trends, challenges & opportunities
Views from AAPS 2022
The Personalized Medicine Pioneer
Inizio’s biotech bromance
The Magic of Drug Development
Why everything starts with great culture
The orphan drug entrepreneur
The wonder of Wurster technology
Biotech trends you need to know
Biotech briefs
Africa’s biotech butterfly
The global pharma leader with an eye on societal impact
From PhD to Pioneer
Supply chain challenges and trends
Chats from CPhI North America
The BioPharmGuy
Chronicles of Swiss Biotech day
From CDMO builder to CDMO creator
Built in Boston, now rebuilding businesses
In the trenches of pharma manufacturing
From Sweden with Science
The niche, niche CDMO with enviable patient reach
Diaries of DCAT
Finland’s Viral Vector Manufacturer of Happinesses
From corporate rebel to CDMO entrepreneur
Mr digital transformation
The Latin American logistics leader
The opportunistic entrepreneur
The Floundering Founder, a lifetime of knowledge for as little as a pound/dollar.
From Pharmacy to $1B family-owned CDMO
Roundtable: M&A trends in CDMO
The UK’s hidden life science gem
Meet the potent powder expert
Physician. Scientist. Entrepreneur.
Hollywood DVDs to biotech drugs
The big pharma sourcing specialist
The Cleanroom Veteran
The 4Cs every CDMO vendor should know
What next for trade events?
The life science dating agent
A little, big announcement...
The CDMO start-up... with a heck of a track record
From Big Pharma to CDMO leader
The change optimist
The Public Health vaccine specialist
The academic turned biopharma innovator
From chemist to consultant
The unique general
The Stickability factor
Poacher turned gamekeeper, turned hybrid
The humble leader
The understated, elite vaccine scientist
Creating a healthy culture
40 at 40
From Pfizer to CDMO start-up
Expanding drug dosage possibilities…
From Teesside Uni to global leader
The accidental CDMO
The passionate problem solver
The entrepreneurial scientist
The sales guru
Marathons. Wine. And 30 years in healthcare.
The industry guru
10 Trends for 2021
The CDMO Disrupter
The biologic CDMO growth guy
Leading M&A at a top-5 global CDMO
The virotherapy virtuoso
Roundtable: Collaboration and driving efficiency
Roundtable: Latest trends in CDMO
Roundtable: Clinical trials in 2020 and beyond
Roundtable: Global geography and the pharma and bio supply chain
Scientist & champion powerlifter
From fax to SaaS: digitising the the pharma supply chain
Successful outsourcing partnerships: now and then
Old world solutions won’t work for new world problems
Looking towards the future: A continuous mindset
Life in a boutique, specialist CDMO
Owning your authenticity
Building robust and scalable systems
Entrepreneurship in the life science space
Advocating for the CDMO sector
The benefits of postponement packaging
Taking the family-owned CDMO global
The increasing demand for HPAPI
A CDMO on the Covid-19 frontline
Learnings from 30 years in the CDMO space
The importance of positive, disruptive thinking
The value of diversity In pharma
Life as a journalist in the space
What is driving the demand for spray drying?
A Generation of Pharma Entrepreneurs
Leading a top tier CDMO
Intro to molecule to market